Scholarlink

<p>Most symptomatic breast findings (94–97%) are benign. The heterogeneous group of non-malignant breast tumors (fibrocystic mastopathy, adenoma, fibroadenoma, breast cyst, mesenchymal tumor, B3-lesion, gynecomastia) can originate from glandular, fatty, connective, and surrounding skin tissue. The diagnosis is based on a combination of various findings. In addition to patient ’s history, clinical findings (including lump formation, dys-/hyperesthesia, pain, nipple discharge, skin changes), and breast imaging, interventional tissue sampling finally provides conclusive diagnostic evidence. Differential diagnoses include malignancy, inflammation, hematoma, seroma, fat tissue necrosis, scar, foreign body, and diseases/tumors of dermatological origin. Treatment is by far necessary for every breast tumor. Rather, the indication for excision may be based on clinical symptoms (e.g., growth), histology, and/or the patient’s preference for surgery. The long-term prognosis determines the individualized follow-up for patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Benigne tumoröse Brustveränderungen

  • 期刊论文

  • 发表日期：

    2026年4月28日

查看全文
  • Alexander Strauss

摘要

Most symptomatic breast findings (94–97%) are benign. The heterogeneous group of non-malignant breast tumors (fibrocystic mastopathy, adenoma, fibroadenoma, breast cyst, mesenchymal tumor, B3-lesion, gynecomastia) can originate from glandular, fatty, connective, and surrounding skin tissue. The diagnosis is based on a combination of various findings. In addition to patient ’s history, clinical findings (including lump formation, dys-/hyperesthesia, pain, nipple discharge, skin changes), and breast imaging, interventional tissue sampling finally provides conclusive diagnostic evidence. Differential diagnoses include malignancy, inflammation, hematoma, seroma, fat tissue necrosis, scar, foreign body, and diseases/tumors of dermatological origin. Treatment is by far necessary for every breast tumor. Rather, the indication for excision may be based on clinical symptoms (e.g., growth), histology, and/or the patient’s preference for surgery. The long-term prognosis determines the individualized follow-up for patients.